Outcomes in patients clinical trials phase ii as topic. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Organisms1

Diseases41

Neoplasms Disease Progression Lung Neoplasms Recurrence Neoplasm Recurrence, Local Breast Neoplasms Neoplasm Metastasis Neutropenia Carcinoma, Non-Small-Cell Lung Stroke Nausea Leukopenia Postoperative Complications Acute Disease Colorectal Neoplasms Brain Neoplasms Chronic Disease Thrombocytopenia Drug-Related Side Effects and Adverse Reactions Prostatic Neoplasms Melanoma HIV Infections Ovarian Neoplasms Pain Vomiting Fatigue Myocardial Infarction Kidney Neoplasms Hematologic Diseases Carcinoma, Squamous Cell Liver Neoplasms Head and Neck Neoplasms Stomach Neoplasms Carcinoma, Renal Cell Peritoneal Neoplasms Cardiovascular Diseases Pancreatic Neoplasms Diarrhea Sarcoma Heart Failure Carcinoma

Chemicals and Drugs55

Antineoplastic Agents Deoxycytidine Paclitaxel Placebos Cisplatin Fluorouracil Taxoids Antibodies, Monoclonal, Humanized Organoplatinum Compounds Camptothecin Antineoplastic Agents, Phytogenic Antibodies, Monoclonal Carboplatin Antimetabolites, Antineoplastic Doxorubicin Vinblastine Quinazolines Dacarbazine Cyclophosphamide Leucovorin Biological Markers Drug Combinations Antineoplastic Agents, Alkylating Drugs, Investigational Benzenesulfonates Phenylurea Compounds Etoposide Niacinamide Angiogenesis Inhibitors Tumor Markers, Biological Epothilones Vincristine Tegafur Protein Kinase Inhibitors Pyrroles Ifosfamide Pyridines Recombinant Proteins Epirubicin Thalidomide Oxonic Acid Pyrimidines Prednisone Pyrazines Anti-Bacterial Agents Antibodies, Monoclonal, Murine-Derived Methotrexate Immunosuppressive Agents Fibrinolytic Agents NAD(P)H Dehydrogenase (Quinone)Cancer Vaccines Piperazines Anthracyclines Anticoagulants Antibiotics, Antineoplastic

Analytical, Diagnostic and Therapeutic Techniques and Equipment93

Clinical Trials as Topic Treatment Outcome Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Research Design Antineoplastic Combined Chemotherapy Protocols Drug Administration Schedule Clinical Trials, Phase I as Topic Double-Blind Method Randomized Controlled Trials as Topic Follow-Up Studies Prospective Studies Survival Analysis Pregnancy Outcome Controlled Clinical Trials as Topic Infusions, Intravenous Survival Rate Patient Selection Prognosis Retrospective Studies Combined Modality Therapy Multicenter Studies as Topic Disease-Free Survival Drug Evaluation Risk Factors Placebos Administration, Oral Clinical Protocols Kaplan-Meier Estimate Severity of Illness Index Neoplasm Staging Single-Blind Method Endpoint Determination Pilot Projects Risk Assessment Drug Therapy, Combination Sample Size Cohort Studies Feasibility Studies Clinical Trials, Phase IV as Topic Maximum Tolerated Dose Predictive Value of Tests Reproducibility of Results Treatment Failure Early Termination of Clinical Trials Remission Induction Salvage Therapy Multivariate Analysis Chemotherapy, Adjuvant Meta-Analysis as Topic Pain Measurement Proportional Hazards Models Data Interpretation, Statistical Logistic Models Analysis of Variance Questionnaires Incidence Chi-Square Distribution Statistics, Nonparametric Regression Analysis Exercise Therapy Length of Stay Glasgow Outcome Scale Probability Longitudinal Studies Cross-Over Studies Sensitivity and Specificity Magnetic Resonance Imaging Area Under Curve Interviews as Topic Registries Random Allocation Odds Ratio Models, Statistical Program Evaluation Neoadjuvant Therapy Drug Approval Confidence Intervals Disability Evaluation Injections, Intravenous Data Collection Statistics as Topic Immunotherapy Radiotherapy, Adjuvant Phytotherapy Hospitalization Tomography, X-Ray Computed Activities of Daily Living Molecular Targeted Therapy Linear Models Risk Cross-Sectional Studies Injections, Subcutaneous

Psychiatry and Psychology6

Patient Compliance Pain Cognitive Therapy Decision Making Health Knowledge, Attitudes, Practice Counseling

Phenomena and Processes16

Time Factors Metabolic Detoxication, Phase II Pregnancy Outcome Dose-Response Relationship, Drug Maximum Tolerated Dose Pregnancy Recovery of Function Drug Resistance, Neoplasm Chi-Square Distribution Pain Probability Sensitivity and Specificity Area Under Curve Odds Ratio Algorithms Risk

Disciplines and Occupations6

Outcome Assessment (Health Care)Research Design Evidence-Based Medicine Biomedical Research Medical Oncology Statistics as Topic

Anthropology, Education, Sociology and Social Phenomena9

Quality of Life Patient Education as Topic Informed Consent Drug Approval United States Food and Drug Administration National Institutes of Health (U.S.)Activities of Daily Living Health Status National Cancer Institute (U.S.)

Technology, Industry, Agriculture2

Dietary Supplements Drug Industry

Humanities1

Quality of Life

Information Science16

Survival Rate Periodicals as Topic Review Literature as Topic Data Interpretation, Statistical Questionnaires Incidence Abstracting and Indexing as Topic Glasgow Outcome Scale Interviews as Topic Registries Textbooks as Topic Terminology as Topic Data Collection Internet Publishing Algorithms

Named Groups3

Infant, Newborn Research Subjects Patient Dropouts

Health Care92

Clinical Trials as Topic Treatment Outcome Clinical Trials, Phase II as Topic Outcome Assessment (Health Care)Clinical Trials, Phase III as Topic Clinical Trials, Phase I as Topic Double-Blind Method Randomized Controlled Trials as Topic Follow-Up Studies Prospective Studies Survival Analysis Controlled Clinical Trials as Topic Survival Rate Patient Selection Retrospective Studies Multicenter Studies as Topic Disease-Free Survival Risk Factors Clinical Protocols Kaplan-Meier Estimate Severity of Illness Index Single-Blind Method Pilot Projects Outcome and Process Assessment (Health Care)Risk Assessment Sample Size Cohort Studies Feasibility Studies Clinical Trials, Phase IV as Topic Clinical Trials Data Monitoring Committees Predictive Value of Tests Cost-Benefit Analysis Reproducibility of Results Treatment Failure Early Termination of Clinical Trials Practice Guidelines as Topic Congresses as Topic Patient Education as Topic Patient Compliance Multivariate Analysis Guidelines as Topic Age Factors Patient Satisfaction Meta-Analysis as Topic Proportional Hazards Models Data Interpretation, Statistical Logistic Models Analysis of Variance Questionnaires Incidence Safety Chi-Square Distribution Benchmarking Statistics, Nonparametric Intention to Treat Analysis Regression Analysis Length of Stay Glasgow Outcome Scale Probability Patient Participation Longitudinal Studies Informed Consent Research Support as Topic Cross-Over Studies Sensitivity and Specificity Area Under Curve Placebo Effect Interviews as Topic Registries Bias (Epidemiology)Random Allocation Odds Ratio Models, Statistical Program Evaluation United States Food and Drug Administration Confidence Intervals Data Collection Statistics as Topic Hospitalization National Institutes of Health (U.S.)Activities of Daily Living Societies, Medical Sex Factors Linear Models Patient Outcome Assessment Health Knowledge, Attitudes, Practice Risk Health Status Cross-Sectional Studies National Cancer Institute (U.S.)Counseling Health Care Costs

Geographicals8

United States Great Britain Europe Canada Australia Japan Germany Netherlands

Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Psychiatry and Psychology Phenomena and Processes Disciplines and Occupations Anthropology, Education, Sociology and Social Phenomena Technology, Industry, Agriculture Humanities Information Science Named Groups Health Care Geographicals

Clinical Trials as Topic Treatment Outcome Clinical Trials, Phase II as Topic Outcome Assessment (Health Care)Clinical Trials, Phase III as Topic Research Design Antineoplastic Combined Chemotherapy Protocols Drug Administration Schedule Clinical Trials, Phase I as Topic Double-Blind Method Time Factors Randomized Controlled Trials as Topic Follow-Up Studies Metabolic Detoxication, Phase II Antineoplastic Agents Prospective Studies Survival Analysis Pregnancy Outcome Controlled Clinical Trials as Topic Infusions, Intravenous Survival Rate Patient Selection Neoplasms Prognosis Retrospective Studies Combined Modality Therapy Multicenter Studies as Topic Deoxycytidine Disease-Free Survival Drug Evaluation Paclitaxel Risk Factors Disease Progression Dose-Response Relationship, Drug Quality of Life United States Placebos Administration, Oral Cisplatin Clinical Protocols Kaplan-Meier Estimate Lung Neoplasms Severity of Illness Index Fluorouracil Taxoids Recurrence Neoplasm Staging Evidence-Based Medicine Single-Blind Method Endpoint Determination Pilot Projects Neoplasm Recurrence, Local Outcome and Process Assessment (Health Care)Antibodies, Monoclonal, Humanized Risk Assessment Drug Therapy, Combination Breast Neoplasms Neoplasm Metastasis Sample Size Cohort Studies Feasibility Studies Clinical Trials, Phase IV as Topic Clinical Trials Data Monitoring Committees Maximum Tolerated Dose Organoplatinum Compounds Pregnancy Camptothecin Antineoplastic Agents, Phytogenic Neutropenia Antibodies, Monoclonal Predictive Value of Tests Cost-Benefit Analysis Carboplatin Infant, Newborn Reproducibility of Results Carcinoma, Non-Small-Cell Lung Treatment Failure Periodicals as Topic Stroke Early Termination of Clinical Trials Antimetabolites, Antineoplastic Remission Induction Salvage Therapy Nausea Practice Guidelines as Topic Congresses as Topic Leukopenia Patient Education as Topic Patient Compliance Doxorubicin Multivariate Analysis Postoperative Complications Guidelines as Topic Vinblastine Age Factors Chemotherapy, Adjuvant Patient Satisfaction Quinazolines Meta-Analysis as Topic Dacarbazine

No FAQ available that match "outcomes in patients clinical trials phase ii as topic"